Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.
1. A method for reducing blood phenylalanine concentration in a patient with phenylketonuria (PKU), comprising subcutaneously administering to the patient a pegylated Anabaena variabilis phenylalanine ammonia-lyase (AvPAL) variant having the amino acid sequence of SEQ ID NO: 11, wherein the method comprises at least three steps:
(a) subcutaneously administering to the patient the pegylated AvPAL variant at an induction dosage of about 2.5 mg per week, wherein the pegylated AvPAL variant is administered once weekly, and wherein the induction dosage is administered for between about 4 weeks to about 8 weeks followed by
(b) subcutaneously administering to the patient the pegylated AvPAL variant at a titration dosage in the range of 5 mg per week to 70 mg per week, wherein the pegylated AvPAL variant is administered once to seven times weekly, and wherein the titration dosage is administered for between about 4 weeks to about 8 weeks; followed by
(c) subcutaneously administering to the patient the pegylated AvPAL variant at a maintenance dosage in the range of about 140 mg per week to about 280 mg per week, wherein the maintenance dosage is administered for between about 24 weeks to about 40 weeks.
2. The method of claim 1 , wherein the induction dosage is administered for about 4 weeks.
3. The method of claim 1 , wherein the titration dosage is administered for about 5 weeks.
4. The method of claim 1 , wherein the method further comprises assessing the blood phenylalanine concentration prior to administering the induction dosage.
5. The method of claim 1 , wherein the method further comprises assessing the blood phenylalanine concentration after administration of one or more dosages.
6. The method of claim 5 , wherein the method further comprises adjusting the dosage based on the blood phenylalanine concentration.
7. The method of claim 6 , wherein the dosage is adjusted to attain a blood phenylalanine concentration of below 600 μM.
8. The method of claim 5 , wherein the method further comprises adjusting the titration dosage based on the blood phenylalanine concentration.
9. The method of claim 8 , wherein the titration dosage is adjusted to attain a blood phenylalanine concentration of below 600 μM.
10. The method of claim 1 , wherein the maintenance dosage is administered for about 40 weeks.
11. The method of claim 1 , wherein the method further comprises assessing the blood phenylalanine concentration after administration of one or more maintenance dosages.
12. The method of claim 11 , wherein the method further comprises adjusting the maintenance dosage based on the blood phenylalanine concentration.
13. The method of claim 12 , wherein the maintenance dosage is adjusted to attain a blood phenylalanine concentration of below about 600 μM.
14. The method of claim 1 , wherein the patient is an adult.